دورية أكاديمية
أعرض في EDS

Development of Targeted Alpha Particle Therapy for Solid Tumors.

التفاصيل البيبلوغرافية
العنوان: Development of Targeted Alpha Particle Therapy for Solid Tumors.
المؤلفون: Tafreshi NK; Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Doligalski ML; Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Tichacek CJ; Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Pandya DN; Department of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA., Budzevich MM; Small Animal Imaging Laboratory, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., El-Haddad G; Depts. of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Khushalani NI; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA., Moros EG; Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Physics, University of South Florida, Tampa, FL 33612, USA.; Department of Oncologic Sciences, University of South Florida, Tampa, FL 33612, USA., McLaughlin ML; Department of Pharmaceutical Sciences, West Virginia University, Health Sciences Center, Morgantown, WV & Modulation Therapeutics Inc., 64 Medical Center Drive, Morgantown, WV 26506, USA., Wadas TJ; Department of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA., Morse DL; Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Physics, University of South Florida, Tampa, FL 33612, USA.; Small Animal Imaging Laboratory, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Oncologic Sciences, University of South Florida, Tampa, FL 33612, USA.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2019 Nov 26; Vol. 24 (23). Date of Electronic Publication: 2019 Nov 26.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Alpha Particles/*therapeutic use , Neoplasms/*radiotherapy , Radiopharmaceuticals/*therapeutic use, Animals ; Antibodies, Monoclonal/therapeutic use ; Humans ; Radioisotopes/therapeutic use ; Radiometry/methods
مستخلص: Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface receptors. Because of the high linear energy transfer (LET) and short range of alpha (α) particles in tissue, cancer cells can be significantly damaged while causing minimal toxicity to surrounding healthy cells. Recent clinical studies have demonstrated the remarkable efficacy of TAT in the treatment of metastatic, castration-resistant prostate cancer. In this comprehensive review, we discuss the current consensus regarding the properties of the α-particle-emitting radionuclides that are potentially relevant for use in the clinic; the TAT-mediated mechanisms responsible for cell death; the different classes of targeting moieties and radiometal chelators available for TAT development; current approaches to calculating radiation dosimetry for TATs; and lead optimization via medicinal chemistry to improve the TAT radiopharmaceutical properties. We have also summarized the use of TATs in pre-clinical and clinical studies to date.
References: J Nucl Med. 2004 Jan;45(1):129-37. (PMID: 14734685)
PLoS One. 2009 May 27;4(5):e5715. (PMID: 19479088)
Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644. (PMID: 29713762)
Tumour Biol. 2012 Jun;33(3):573-90. (PMID: 22143940)
Biochemistry. 1993 Mar 2;32(8):2104-10. (PMID: 8383534)
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8444-8. (PMID: 17488826)
Nat Med. 1997 Mar;3(3):306-12. (PMID: 9055858)
Cancer Res. 1992 Jun 15;52(12):3402-8. (PMID: 1596900)
Theranostics. 2016 Mar 01;6(5):698-709. (PMID: 27022417)
Nat Nanotechnol. 2013 Oct;8(10):763-71. (PMID: 24077028)
J Nucl Med. 1999 Nov;40(11):1935-46. (PMID: 10565792)
Anticancer Res. 2004 Jan-Feb;24(1):101-5. (PMID: 15015582)
Nucl Med Biol. 2000 Jan;27(1):93-100. (PMID: 10755652)
Health Phys. 2014 Apr;106(4):494-504. (PMID: 24562070)
Cancer Biother Radiopharm. 2014 Oct;29(8):323-9. (PMID: 25226447)
N Engl J Med. 2013 Jul 18;369(3):213-23. (PMID: 23863050)
Mol Imaging Biol. 2016 Feb;18(1):1-17. (PMID: 26754790)
Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Aug;36(2):149-60. (PMID: 315389)
Eur J Nucl Med. 2001 Apr;28(4):534-9. (PMID: 11357506)
Clin Cancer Res. 2006 Jun 15;12(12):3843-50. (PMID: 16778112)
Anticancer Res. 2001 Jan-Feb;21(1A):409-12. (PMID: 11299770)
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19. (PMID: 25070685)
Science. 2001 Nov 16;294(5546):1537-40. (PMID: 11711678)
Med Phys. 1994 Feb;21(2):299-302. (PMID: 8177164)
J Nucl Med. 2017 Nov;58(11):1709-1710. (PMID: 28935836)
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. (PMID: 17062709)
Ann Oncol. 2016 May;27(5):868-74. (PMID: 26912557)
Clin Genitourin Cancer. 2018 Apr;16(2):149-154. (PMID: 29196208)
Cancer Res. 2009 Mar 15;69(6):2408-15. (PMID: 19244101)
Adv Space Res. 1986;6(11):89-96. (PMID: 11537251)
Org Biomol Chem. 2005 Feb 7;3(3):454-61. (PMID: 15678183)
Blood. 2013 May 2;121(18):3759-67. (PMID: 23471305)
Curr Radiopharm. 2018;11(3):200-208. (PMID: 29732998)
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):572-9. (PMID: 17869670)
Medchemcomm. 2018 Jun 6;9(7):1155-1163. (PMID: 30109003)
Bioconjug Chem. 2004 Jan-Feb;15(1):41-9. (PMID: 14733582)
Adv Drug Deliv Rev. 2008 Sep;60(12):1402-6. (PMID: 18541332)
J Urol. 2015 Dec;194(6):1537-47. (PMID: 26196735)
Int J Nanomedicine. 2010 Oct 05;5:783-802. (PMID: 21042424)
J Korean Neurosurg Soc. 2016 Mar;59(2):117-21. (PMID: 26962416)
Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717. (PMID: 28963750)
Biochem Biophys Res Commun. 2018 Dec 2;506(4):1078-1084. (PMID: 30409432)
Cancer Res. 2009 Dec 1;69(23):8941-8. (PMID: 19920193)
Blood. 2010 Nov 18;116(20):4231-9. (PMID: 20702781)
Nucl Med Biol. 2005 Oct;32(7):741-7. (PMID: 16243650)
Clin Cancer Res. 2008 Jun 1;14(11):3555-61. (PMID: 18519789)
Cancer Biother Radiopharm. 2014 Feb;29(1):12-7. (PMID: 24229395)
J Nucl Med. 2005 Jan;46 Suppl 1:38S-47S. (PMID: 15653650)
Adv Exp Med Biol. 2014;804:291-304. (PMID: 24924181)
Life Sci. 1982 Sep 13;31(11):1133-40. (PMID: 6128648)
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2264-2273. (PMID: 29998419)
Biochim Biophys Acta. 2010 Jan;1805(1):105-17. (PMID: 19931353)
Bioconjug Chem. 2008 Jun;19(6):1274-82. (PMID: 18505278)
Nucl Med Biol. 2003 Aug;30(6):581-95. (PMID: 12900284)
Oncotarget. 2016 Dec 27;7(52):86937-86947. (PMID: 27893426)
Oncotarget. 2017 Apr 7;8(34):56311-56326. (PMID: 28915592)
J Nucl Med. 2005 Nov;46(11):1907-15. (PMID: 16269606)
Bioconjug Chem. 2011 Apr 20;22(4):766-76. (PMID: 21434681)
Appl Radiat Isot. 2002 Dec;57(6):841-7. (PMID: 12406626)
J Nucl Med. 1999 Jan;40(1):11S-36S. (PMID: 9935083)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622. (PMID: 30498897)
Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Aug;36(2):137-48. (PMID: 315388)
J Nucl Med. 1999 Jan;40(1):166-76. (PMID: 9935073)
J Nucl Med. 2004 Oct;45(10):1776-83. (PMID: 15471848)
Eur J Nucl Med. 2001 Apr;28(4):541-61. (PMID: 11357507)
Int J Mol Sci. 2018 Mar 21;19(4):null. (PMID: 29561763)
Clin Cancer Res. 2009 Feb 1;15(3):1069-75. (PMID: 19188182)
Phys Med Biol. 2013 Apr 21;58(8):2491-508. (PMID: 23514870)
Curr Radiopharm. 2011 Oct;4(4):306-20. (PMID: 22202153)
Cancer Biother Radiopharm. 2004 Apr;19(2):135-47. (PMID: 15186593)
Clin Nucl Med. 2013 Dec;38(12):966-71. (PMID: 24212441)
Cancer Res. 1999 Jun 1;59(11):2635-43. (PMID: 10363986)
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147. (PMID: 30151743)
Mol Psychiatry. 2014 Jan;19(1):20-9. (PMID: 24166406)
Trans Am Clin Climatol Assoc. 1964;75:111-6. (PMID: 21408638)
Cancer Res. 2003 Aug 15;63(16):5084-90. (PMID: 12941838)
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):897-903. (PMID: 16467104)
Cancer Res. 2005 Jun 1;65(11):4888-95. (PMID: 15930310)
Rev Neurosci. 2014;25(5):663-73. (PMID: 24960151)
Mol Cancer Ther. 2017 Oct;16(10):2191-2200. (PMID: 28619756)
Exp Hematol Oncol. 2014 Sep 08;3:23. (PMID: 25243101)
Cancer Biol Ther. 2015;16(10):1526-34. (PMID: 26177233)
Front Oncol. 2014 Jan 14;3:324. (PMID: 24459634)
J Nucl Med. 2008 May;49(5):823-9. (PMID: 18413404)
Nucl Med Biol. 2018 Mar;58:67-73. (PMID: 29413459)
Mol Imaging Biol. 2016 Apr;18(2):153-65. (PMID: 26754791)
J Nucl Med. 2015 Jun;56(6):897-900. (PMID: 25931476)
Front Oncol. 2013 Jun 20;3:159. (PMID: 23802097)
Nucl Med Biol. 1997 Apr;24(3):255-61. (PMID: 9228660)
J Nucl Med. 2009 Jul;50(7):1153-60. (PMID: 19525452)
Cancer Biother Radiopharm. 2013 Feb;28(1):1-20. (PMID: 23075373)
Dose Response. 2006 Aug 25;4(4):283-90. (PMID: 18648593)
Health Phys. 1985 Dec;49(6):1177-87. (PMID: 4077520)
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):505-10. (PMID: 24196919)
Eur J Cancer. 2012 Mar;48(5):678-86. (PMID: 22341993)
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):271-8. (PMID: 11516878)
J Nucl Med. 2010 Jul;51(7):1123-30. (PMID: 20554722)
AIMS Med Sci. 2015;2(3):228-245. (PMID: 26858987)
Nucl Med Biol. 1999 Jul;26(5):581-9. (PMID: 10473198)
Cancer Res. 1994 Sep 1;54(17):4719-25. (PMID: 8062270)
Nat Med. 2003 Jan;9(1):129-34. (PMID: 12514726)
Curr Radiopharm. 2011 Jul;4(3):214-47. (PMID: 22201710)
Semin Nucl Med. 2008 Sep;38(5):321-34. (PMID: 18662554)
Pharmaceuticals (Basel). 2015 Jun 10;8(2):321-36. (PMID: 26066613)
J Nucl Med. 2015 May;56(5):805-11. (PMID: 25840974)
Acta Oncol. 2003;42(5-6):620-33. (PMID: 14596519)
Nucl Med Biol. 2007 Oct;34(7):779-85. (PMID: 17921029)
J Nucl Med. 2014 Oct;55(10):1636-42. (PMID: 25157044)
Cancer Res. 1994 Aug 15;54(16):4362-70. (PMID: 8044783)
J Nucl Med. 2009 Oct;50(10):1700-8. (PMID: 19793735)
Int J Radiat Biol Relat Stud Phys Chem Med. 1979 Aug;36(2):127-36. (PMID: 315387)
Nucl Instrum Methods Phys Res A. 2014 Dec 11;767:146-152. (PMID: 26166921)
Inorg Chem. 2013 Apr 1;52(7):3445-58. (PMID: 22838498)
Anticancer Res. 2000 Jan-Feb;20(1A):459-62. (PMID: 10769696)
Oncol Rep. 2007 May;17(5):1141-7. (PMID: 17390057)
Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9. (PMID: 15380745)
Blood. 2002 Jul 1;100(1):208-16. (PMID: 12070029)
Clin Cancer Res. 2010 Nov 1;16(21):5303-11. (PMID: 20858843)
J Nucl Med. 2001 Apr;42(4):662-9. (PMID: 11337557)
Nucl Med Biol. 2017 Apr;47:23-30. (PMID: 28104527)
MAbs. 2015;7(1):255-64. (PMID: 25587678)
EJNMMI Res. 2011 Aug 24;1(1):18. (PMID: 22214432)
J Nucl Med. 2017 Oct;58(10):1624-1631. (PMID: 28408529)
Cancer. 2010 Feb 15;116(4 Suppl):1059-66. (PMID: 20127951)
J Nucl Med. 2019 Aug;60(8):1124-1133. (PMID: 30733316)
Clin Exp Metastasis. 2012 Oct;29(7):847-52. (PMID: 22760521)
Lancet Oncol. 2014 Jun;15(7):738-46. (PMID: 24836273)
Phys Med Biol. 2000 Aug;45(8):2263-91. (PMID: 10958194)
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138. (PMID: 30232539)
J Nucl Med. 1999 Oct;40(10):1722-7. (PMID: 10520715)
PLoS One. 2013 Jul 29;8(7):e69613. (PMID: 23922757)
Clin Cancer Res. 2007 Mar 15;13(6):1926-35. (PMID: 17363549)
Eur Urol. 2016 Dec;70(6):1080-1081. (PMID: 27554243)
Cancer Manag Res. 2013;5:1-14. (PMID: 23326203)
Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7. (PMID: 17935286)
Eur J Cancer. 2019 Jun;114:107-116. (PMID: 31082669)
Bioconjug Chem. 2002 Sep-Oct;13(5):985-95. (PMID: 12236780)
Bioconjug Chem. 2000 Jul-Aug;11(4):510-9. (PMID: 10898572)
Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1272-81. (PMID: 18404268)
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s. (PMID: 16203804)
Clin Cancer Res. 2005 Aug 1;11(15):5616-21. (PMID: 16061880)
Chem Rev. 2001 Jul;101(7):2019-36. (PMID: 11710239)
EJNMMI Res. 2013 Apr 04;3(1):23. (PMID: 23557183)
Semin Nucl Med. 2016 Mar;46(2):135-46. (PMID: 26897718)
Cancer Biother Radiopharm. 2015 Jun;30(5):195-9. (PMID: 25746633)
Breast Cancer Res Treat. 2014 Jun;145(2):411-8. (PMID: 24728613)
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):93-102. (PMID: 19593562)
J Nucl Med. 2005 Jun;46(6):1023-7. (PMID: 15937315)
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. (PMID: 29115304)
Eur Urol. 2016 Nov;70(5):875-883. (PMID: 27344296)
Med Phys. 2008 Jul;35(7):3062-8. (PMID: 18697529)
J Nucl Med. 2010 Oct;51(10):1616-23. (PMID: 20847171)
Cancer Biother Radiopharm. 2005 Oct;20(5):557-68. (PMID: 16248771)
Nucl Med Biol. 2013 Jul;40(5):592-9. (PMID: 23602604)
Curr Radiopharm. 2018;11(3):223-230. (PMID: 29866026)
Cancer Res. 1992 Oct 15;52(20):5818-20. (PMID: 1394209)
Nucl Med Biol. 2014 May;41 Suppl:e30-5. (PMID: 24759272)
Transl Oncol. 2018 Apr;11(2):259-267. (PMID: 29413758)
Oncotarget. 2017 Jun 27;8(26):42997-43007. (PMID: 28562337)
Blood. 2015 Mar 26;125(13):2111-9. (PMID: 25628467)
Nucl Med Biol. 2016 Jan;43(1):35-41. (PMID: 26702785)
J Oncol. 2010;2010:394913. (PMID: 19859581)
J Nucl Med. 2014 Sep;55(9):1492-8. (PMID: 24982438)
AJR Am J Roentgenol. 2014 Aug;203(2):253-60. (PMID: 25055256)
Clin Cancer Res. 2019 Jan 15;25(2):868-880. (PMID: 30352909)
Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Feb;37(2):135-67. (PMID: 6966263)
J Am Soc Nephrol. 2005 Sep;16(9):2677-89. (PMID: 15987754)
EJNMMI Res. 2016 Dec;6(1):6. (PMID: 26791386)
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):999-1010. (PMID: 29350258)
Chem Commun (Camb). 2018 Mar 8;54(21):2599-2602. (PMID: 29388990)
J Nucl Med. 1996 Feb;37(2):249-52. (PMID: 8667054)
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. (PMID: 17891393)
Clin Cancer Res. 2012 Sep 1;18(17):4522-5. (PMID: 22761465)
Biologics. 2014 Nov 10;8:255-67. (PMID: 25422581)
J Nucl Med. 2018 May;59(5):795-802. (PMID: 29326358)
Lancet Oncol. 2014 Nov;15(12):1397-406. (PMID: 25439694)
Curr Radiopharm. 2011 Oct;4(4):295-305. (PMID: 22202152)
Phys Med Biol. 2011 Feb 7;56(3):721-33. (PMID: 21220845)
Acta Oncol. 2000;39(6):741-5. (PMID: 11130014)
J Nucl Med. 2013 Sep;54(9):1597-604. (PMID: 24003167)
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1102-1110. (PMID: 30637501)
Br J Haematol. 1998 Mar;100(4):637-46. (PMID: 9531328)
Clin Cancer Res. 2009 Feb 1;15(3):865-75. (PMID: 19188157)
Am J Nucl Med Mol Imaging. 2012;2(2):163-73. (PMID: 23133811)
Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):609-16. (PMID: 8621285)
Theranostics. 2011 Jan 12;2011(1):28-29. (PMID: 21499413)
Cancer Biother Radiopharm. 2000 Jun;15(3):219-21. (PMID: 10941528)
Clin Cancer Res. 2004 Oct 15;10(20):6985-92. (PMID: 15501978)
J Nucl Med. 2003 Feb;44(2):252-9. (PMID: 12571218)
Cancer Biother Radiopharm. 2014 Feb;29(1):34-41. (PMID: 24102173)
Onco Targets Ther. 2017 Aug 04;10:3925-3940. (PMID: 28831267)
Mol Cancer Ther. 2016 Jan;15(1):106-113. (PMID: 26586724)
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2256-2263. (PMID: 29785515)
J Nucl Med. 2007 Jul;48(7):1180-9. (PMID: 17607040)
Blood. 2002 Aug 15;100(4):1233-9. (PMID: 12149203)
Curr Pharm Des. 2000 Sep;6(14):1433-55. (PMID: 10903402)
J Nucl Med. 2019 May 17;:null. (PMID: 31101746)
J Nucl Med. 2016 Dec;57(12):1941-1944. (PMID: 27390158)
Clin Cancer Res. 2005 Jun 15;11(12):4451-9. (PMID: 15958630)
Protein Eng Des Sel. 2014 Oct;27(10):317-24. (PMID: 25095796)
PLoS One. 2012;7(2):e31402. (PMID: 22363636)
PLoS One. 2013;8(1):e54531. (PMID: 23349921)
Bioconjug Chem. 2013 Feb 20;24(2):291-9. (PMID: 23330714)
J Nucl Med. 2008 Jan;49(1):30-8. (PMID: 18077533)
Cancer Biother Radiopharm. 2018 Jun;33(5):182-193. (PMID: 29916748)
J Nucl Med. 2019 May;60(5):649-655. (PMID: 30413660)
Radiat Res. 1975 Aug;63(2):226-34. (PMID: 1144688)
J Nucl Med. 2018 Sep 27;:null. (PMID: 30262520)
Urologe A. 2017 Jan;56(1):40-43. (PMID: 27885456)
Clin Cancer Res. 2004 Jul 1;10(13):4489-97. (PMID: 15240541)
J Nucl Med. 2004 Aug;45(8):1358-65. (PMID: 15299062)
Cancer Biother Radiopharm. 2005 Jun;20(3):325-32. (PMID: 15989479)
Transl Androl Urol. 2018 Jun;7(3):436-444. (PMID: 30050802)
Kidney Int. 1979 Sep;16(3):251-70. (PMID: 393891)
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3914S-21S. (PMID: 14506189)
Adv Drug Deliv Rev. 2008 Sep;60(12):1371-82. (PMID: 18514364)
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):312-22. (PMID: 21072513)
J Nucl Med. 2004 Feb;45(2):253-60. (PMID: 14960644)
Adv Cancer Res. 2014;124:213-34. (PMID: 25287690)
Cell Death Differ. 2018 Mar;25(3):486-541. (PMID: 29362479)
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):602-12. (PMID: 22237842)
Cancer Res. 2011 Feb 1;71(3):1009-18. (PMID: 21245097)
Phys Med Biol. 2012 Feb 7;57(3):771-83. (PMID: 22252144)
Front Med (Lausanne). 2015 Nov 04;2:76. (PMID: 26582128)
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1364-1371. (PMID: 29644393)
Br J Cancer. 1955 Dec;9(4):539-49. (PMID: 13304213)
J Nucl Med. 2005 Mar;46(3):464-71. (PMID: 15750160)
Cancer Res. 2010 Nov 15;70(22):9277-86. (PMID: 21045141)
Bioconjug Chem. 2015 Nov 18;26(11):2243-8. (PMID: 26161903)
Immunotherapy. 2011 Sep;3(9):1041-50. (PMID: 21913827)
Clin Genitourin Cancer. 2013 Mar;11(1):20-6. (PMID: 23021204)
J Nucl Med. 2010 Feb;51(2):311-28. (PMID: 20080889)
Expert Opin Drug Deliv. 2014 Dec;11(12):1939-54. (PMID: 25035968)
Nat Rev Clin Oncol. 2011 Nov 08;8(12):720-34. (PMID: 22064461)
Mol Pharm. 2019 Sep 3;16(9):3904-3915. (PMID: 31318566)
EJNMMI Res. 2017 Dec;7(1):57. (PMID: 28721684)
J Nucl Med. 2007 Jun;48(6):1008-16. (PMID: 17504874)
Clin Cancer Res. 2008 Feb 1;14(3):875-82. (PMID: 18245551)
Eur J Nucl Med Mol Imaging. 2005 May;32(5):601-14. (PMID: 15841373)
Cancer Biol Ther. 2007 Jun;6(6):846-52. (PMID: 17495524)
Cancer Biother Radiopharm. 2018 May;33(4):155-165. (PMID: 29694246)
Curr Radiopharm. 2011 Jul;4(3):177-85. (PMID: 22201707)
Laryngoscope. 2007 Jun;117(6):1013-8. (PMID: 17440426)
Appl Radiat Isot. 2016 Dec;118:366-374. (PMID: 27776333)
Clin Genitourin Cancer. 2019 Apr;17(2):79-87. (PMID: 30558834)
فهرسة مساهمة: Keywords: chelation; clinical studies; mechanism of cell death; medicinal chemistry; radiation dosimetry; solid tumors; targeted alpha-particle therapy; targeting moieties
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Radioisotopes)
0 (Radiopharmaceuticals)
تواريخ الأحداث: Date Created: 20191130 Date Completed: 20200417 Latest Revision: 20200417
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6930656
DOI: 10.3390/molecules24234314
PMID: 31779154
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules24234314